::: Pharminox appoints Dr Marc Hummersone to its Board of Directors
Dr Marc Hummersone, Marc Hummersone PhD, Dr Hummersone graduated, Pharminox Limited, DNA repair company, calibre discovery research team, development of Pharminox, discovery research operations, aspects of discovery research, UK-based cancer drug discovery

::: Abraxis Bioscience and Specialised Therapeutics Announce Approval to Market Abraxane for Metastatic Breast Cancer in New Zealand
treatment of metastatic breast cancer, Australia ABRAXANE, marketing ABRAXANE, ABRAXANE available, treatment of breast cancer, reimbursement approval of ABRAXANE, New Zealand women, Specialised Therapeutics Australia, New Zealand pharmaceutical reimbursement authority, New Zealand Medicines

::: Daiichi Sankyo Ends Shareholder Agreement with Sanofi Pasteur S.A.
Daiichi Sankyo Company, SPDS Vaccine, Daiichi Sankyo Ends Shareholder Agreement, Daiichi Sankyo 50%, vaccine ActHIB, conjugate vaccine, IPV-DTP quad combination vaccine, SA Group, SPDS becoming, Sanofi Pasteur Daiichi Sankyo Vaccine Co

::: Data on Basilea's Toctino® in daily medical practice in Germany presented at dermatology congress
treatment of severe chronic hand eczema, severe chronic hand eczema unresponsive, treatment of severe CHE, sample of 680 severe CHE patients, mg Toctino, TOCCATA observational study, clinical profile of Toctino, show effective clearing of severe CHE, first treatment, non-interventional TOCCATA study

::: Announcement Regarding the Establishment of a Joint Venture Company between Daiichi Sankyo and The Kitasato Institute
significance of the new joint venture company, Significance of the Joint Venture Company, Daiichi Sankyo Company, establishment of the joint venture company, addition of the joint venture business, Kitasato Institute Research Center, major Japanese pharmaceutical company, Japanese vaccine industry, combining Kitasato, vaccine business activities